Acadia Pharmaceuticals Secures Exclusive License for SAN711, a Novel Essential Tremor Treatment

Licensing Agreement:
Acadia Pharmaceuticals has entered into an exclusive worldwide licensing agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator aimed at treating essential tremor13.

Financial Terms:
The agreement includes a $28 million upfront payment to Saniona, with potential milestone payments up to $582 million and tiered royalties on net sales13.

Development Plans:
Acadia plans to initiate a Phase 2 study of SAN711 for essential tremor in 2026, leveraging its expertise in developing treatments for central nervous system disorders13.

Market Opportunity:
Essential tremor represents an attractive market opportunity due to the lack of recent advancements in treatments, making SAN711 a potential game-changer if successful13.

Financial Position:
Acadia Pharmaceuticals has a strong financial position, with a market capitalization of $2.7 billion and significant revenue growth, supporting its investment in new drug candidates like SAN7113.

Sources:

1. https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-announces-exclusive-license-agreement-with-ku45gqes5iq4.html

3. https://www.investing.com/news/company-news/acadia-licenses-novel-treatment-for-essential-tremor-93CH-3743152